Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 51 clinical trials
Taiwan Real-world Low-dose Computed Tomography Screening behavIor and Outcome Research for High Risk Subjects Based on Health Promotion Administration-part A: Questionnaire Survey -Part B: LDCT Screening Outcome and Management (TRIO)

, and adenocarcinoma histology. This unique risk group is likely to have distinct molecular drivers, especially EGFR, ALK, and ROS1 mutations.In National Taiwan Cancer Registry data, more than half (53

ROS1
EGFR
cigarette smoke
lung carcinoma
cancer
  • 0 views
  • 24 Oct, 2022
  • 1 location
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …

nitrosoureas
blood transfusion
pleural effusion
absolute neutrophil count
chemotherapeutic agents
  • 1032 views
  • 25 Oct, 2022
  • 108 locations
Study of Lorlatinib in ROS1 Rearranged NSCLC

This is a phase II, multi-center, single arm study of lorlarinib as a single agent in patients with ROS1-rearranged advanced NSCLC.

ROS1
kidney function test
proto-oncogene tyrosine-protein kinase ros
measurable disease
cancer chemotherapy
  • 0 views
  • 27 Apr, 2022
  • 1 location
Study of Crizotinib for ROS1 and MET Activated Lung Cancer

called ROS1 or MET. The purpose of this study is to look at how effective crizotinib is at treating ROS1 or MET mutated non-small cell lung cancer. Crizotinib, also called XALKORI, is a

ROS1
crizotinib
squamous non-small cell lung cancer
measurable disease
cancer
  • 0 views
  • 18 Dec, 2021
  • 1 location
A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene

The purpose of the study is to evaluate safety, pharmacokinetics and efficacy of AB-106 monotherapy in the treatment of advanced NSCLC.

ROS1
proto-oncogene tyrosine-protein kinase ros
brain metastases
serum bilirubin level
crizotinib
  • 0 views
  • 27 Jun, 2021
  • 1 location
Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE) (ROSALINE)

synthetic lethality interactions has identified ROS1 as a potential target. In vivo, ROS1 inhibitors produced profound antitumor effects in multiple models of E-cadherin-defective breast cancer, providing

  • 0 views
  • 26 May, 2022
  • 10 locations
A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer

multiple oral administrations in advanced NSCLC subjects with ALK rearrangement or ROS1 rearrangement, and to initially explore the efficacy of XZP-3621.The study was divided into two parts: dose

  • 0 views
  • 29 Sep, 2021
  • 1 location
A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors

A phase I/II study to examine the safety, tolerability, pharmacokinetics and efficacy of XZP-5955 tablets in patients with advanced solid tumors harboring NTRK or ROS1 gene fusion

  • 0 views
  • 07 Oct, 2022
  • 1 location
An Open Label Multi-center Phase I Clinical Study to Evaluate the Safety Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK ROS1 or ALK Gene Fusion Mutations.

This research study is done to test the safety, effectiveness and pharmacokinetic characteristics of SIM1803-1A in patients with locally advanced/metastatic solid tumors with NTRK, ROS1 or ALK

  • 1 views
  • 30 Jan, 2021
  • 1 location
A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions

This research study is studying a drug as a possible treatment for ALK-positive or ROS1-positive non-small cell lung cancer (NSCLC). The following drug will be involved in this study

ROS1
EGFR
kidney function test
serum bilirubin level
lung carcinoma
  • 0 views
  • 25 Feb, 2022
  • 1 location